ABBV vs ALT

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

ALT exhibits severe financial distress despite strong revenue growth, as evidenced by a Piotroski F-Score of 1/9—indicating poor operational and financial health. The Altman Z-Score is unavailable, but the company's negative profitability metrics (ROE: -50.57%, ROA: -28.17%), massive operating losses, and negative earnings suggest high distress risk. While revenue growth is explosive at 420% YoY, this is not translating into profitability or cash flow, and the stock trades at an extreme Price/Sales of 10,690.50, reflecting speculative valuation. Analysts recommend 'buy' with a $17.22 target, but this is likely driven by pipeline optimism rather than fundamentals. The technical trend is bearish, and insider activity is neutral, offering no conviction.